← Eichor
Condition: Somatostatin Receptor Positive Sstr Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Somatostatin Receptor Positive Sstr

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancr
Phase 3 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT05884255A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Phase 2/Phase 3 · 1 location(s) · Sinotau Pharmaceutical Group · NCT06398444Spanish Series of Patients Treated With the Radionuclide Lutetium177
Phase N/A · 20 location(s) · Sociedad Española de Medicina Nuclear e Imagen Molecular · NCT04949282Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendoc
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06427798"Receptor Radionuclide Therapy With 177Lu-DOTATOC
Phase 2 · 2 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT06045260Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Phase 3 · 65 location(s) · Novartis Pharmaceuticals · NCT06784752Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for
Phase 1 · 1 location(s) · Stanford University · NCT04609592A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in
Phase 3 · 1 location(s) · HTA Co., Ltd. · NCT07057622Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric P
Phase 1 · 5 location(s) · ITM Solucin GmbH · NCT06441331Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Phase 1 · 10 location(s) · National Cancer Institute (NCI) · NCT0568712368-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Phase 4 · 1 location(s) · Weill Medical College of Cornell University · NCT0408170168Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Phase 2 · 1 location(s) · University of Alberta · NCT04888481A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to E
Phase 1/Phase 2 · 1 location(s) · AHS Cancer Control Alberta · NCT03145857Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of th
Phase 3 · 27 location(s) · Grupo Espanol de Tumores Neuroendocrinos · NCT05918302A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tu
Phase 1/Phase 2 · 26 location(s) · Crinetics Pharmaceuticals Inc. · NCT07129252[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors,
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06479811Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression
Phase 2/Phase 3 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05749289Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Phase 1/Phase 2 · 19 location(s) · Perspective Therapeutics · NCT05636618Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumor
Phase 2 · 29 location(s) · National Cancer Institute (NCI) · NCT04665739
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.